logo image

BRIGATINIB

BRIGATINIB

Tablets

ALUNBRIG (brigatinib) is a kinase inhibitor. ALUNBRIG is supplied for oral use as film-coated tablets containing 180 mg, 90 mg or 30 mg of brigatinib and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose,sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide.
ALUNBRIG (brigatinib) Tablets: 180 mg, 90 mg, or 30 mg.
Recommended dosage of Brigatinib is 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.
ALUNBRIG (brigatinib) is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Contact Us

Established in New Delhi, India in 2020, ImpoMed Healthcare has grown over the years from a new start up to one of the Most Preferred Company for Facilitation of the Imported Drugs-Only USFDA/European FDA Approved.

Quick Links

Diseases

Corporate Office